Date
26 September 2023
Challenges and Potential of Generic Drug Companies in Improving Access to Essential Medications
Investment website Best Stocks takes a look at the first report from the Foundation's Generic & Biosimilar Medicines Programme, which consists of in-depth profiles of five major generic drug companies.
Direct links
The article gives an overview of the report's key finding, namely that despite efforts from the five companies profiled there are still far too many patients living in low- and middle-income countries (LMICs) who do have access to the essential medicines they need.
The article also notes that there is a risk of a decline in access if generic manufacturers focus their sights on higher-profit, wealthier markets at the expense of those living in LMICs.
Read the Foundation's report on generic and biosimilar medicine manufacturers.